Straits Times Index
3,162.73 -24.93 (-0.78%) Nikkei
36,818.81 -1,260.89 (-3.31%) Hang Seng
16,142.94 -242.93 (-1.48%) FTSE 100
7,877.05 +29.06 (+0.37%) Bitcoin USD
60,590.35 -1,035.10 (-1.68%) CMC Crypto 200
1,242.90 +357.36 (+37.46%)
Biodesix, Inc. (BDSX)
After hours:
- Simply Wall St.
The recent US$4.0m market cap decrease is likely to have disappointed insiders invested in Biodesix, Inc. (NASDAQ:BDSX)
Key Insights Significant insider control over Biodesix implies vested interests in company growth 53% of the business...
- Business Wire
Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting
LOUISVILLE, Colo., April 09, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, California. These presentations highlight advancements in liquid biopsy technologies that detect cell free DNA (cfDNA) and the clinical value of rapid turnaround time to detect actionable tumor mutations in a real-world clinical set
- Business Wire
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
LOUISVILLE, Colo., April 05, 2024--Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to the public of $1.15 per share. In addition, Biodesix has entered into securities purchase agreements for a concurrent private placement of 760,857 shares of its Series A Non-Voting Convertible Preferred Stock at a price of $46.00 per share. Subject to B
